Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION KRAS mutations, the most frequent gain-of-function alterations in non-small cell lung cancer (NSCLC), are currently emerging as potential predictive therapeutic targets. KRAS-G12C (Kr_G12C) role is of special interest, following the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). METHODS KRAS mutations were assessed in FFPE tissue sections by a microfluidics-based multiplex PCR platform as a component of the previously published ETOP Lungscape 003 Multiplex Mutation study, of clinically annotated, resected, stage I-III NSCLC. In this study, -Kr_G12C mutation prevalence and its association with clinicopathological characteristics, molecular profiles and post-operative patient outcome (Overall Survival (OS), Relapse-free Survival (RFS), Time-to-Relapse (TTR)) was explored. RESULTS KRAS gene was tested in 2055 Lungscape cases (adenocarcinomas: 1014 (49%)) with I/II/III stage distribution: 53%/24%/22%, and median follow-up: 57 months. KRAS mutation prevalence in the adenocarcinoma cohort was 38.0%;95%CI:35.0%-41.0%, with Kr_G12C mutation representing 17.0%;95%CI:14.7%-19.4%. In the "all-histologies" cohort, Kr_G12C prevalence was 10.5%;95%CI:9.2%-11.9%. When adjusting for clinicopathological characteristics, a significant negative prognostic effect of Kr_G12C presence versus other KRAS mutations or non-existence of KRAS mutation was identified in the adenocarcinoma cohort alone and also in the 'all-histology' cohort. For OS in adenocarcinomas: HRG12C_vs_other_KRAS=1.39;95%CI:1.03-1.89;p=0.031 and HRG12C_vs_noKRAS=1.32;95%CI:1.03-1.69;p=0.028 (both also significant in the "all-histologies" cohort) while for TTR: HRG12C_vs_other_KRAS=1.41;95%CI:1.03-1.92;p-value=0.030. Also, among all patients, for RFS: HRG12C_vs_noKRAS=1.27;95%CI:1.04-1.54;p=0.017. CONCLUSION In this large, clinically annotated stage I-III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathological characteristics) among adenocarcinomas as well as in unselected NSCLCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118
Self-citationZer, A., Ding, K., Lee, S. M., Goss, G. D., Seymour, L., Ellis, P. M., Hackshaw, A., Bradbury, P. A., Han, L., O’Callaghan, C. J., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.010 · Cited by 56
Cited by
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Li, Z., Song, Z., Zhao, Y., Wang, P., Jiang, L., Gong, Y., Zhou, J., Jian, H., Dong, X., Zhuang, W., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.015 · Cited by 88
KRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76
“0092) [34], although this evidence has not been further confirmed in other reports [26].”
ResultLi, Z., Dang, X., Huang, D., Jin, S., Li, W., Shi, J., Wang, X., Zhang, Y., Song, Z., Zhang, J., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00110-3 · Cited by 49
Zhang, Y., Li, C., Xia, C., Wah To, K. K., Guo, Z., Ren, C., Wen, L., Wang, F., Fu, L., & Liao, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00955-8 · Cited by 33
“MRTX849 is a potent, highly selective, and covalent KRAS G12C inhibitor, currently under active clinical investigation[53, 54].”
Background
Metadata
- Authors
- Finn, S. P., Addeo, A., Dafni, U., Thunnissen, E., Bubendorf, L., Madsen, L. B., Biernat, W., Verbeken, E., Hernandez-Losa, J., Marchetti, A., Cheney, R., Warth, A., Speel, E.-J. M., Quinn, A. M., Monkhorst, K., Jantus-Lewintre, E., Tischler, V., Marti, N., Dimopoulou, G., Molina-Vila, M. A., Kammler, R., Kerr, K. M., Peters, S., & Stahel, R. A.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 16
- Issue
- 6
- Pages
- 990-1002
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3134146062
- Cited by
- 63
- References
- 9
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.